Rockefeller Capital Management
IBIO icon

Rockefeller Capital Management’s iBio IBIO Stock Holding History

Rockefeller Capital Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed – – 3961
2021
Q4 		$0 Sell
2
-1
-33% -$381 ﹤0.01% 3869
2021
Q3 		$1K Hold
3
– – ﹤0.01% 3578
2021
Q2 		$2K Buy
+3
New +$2.19K ﹤0.01% 3249

Other funds holding IBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rockefeller Capital Management's IBIO Position: Q1 2022 in Review

Rockefeller Capital Management sold out of iBio (IBIO) in Q1 2022, closing a stake of 2 shares.

Rockefeller Capital Management first reported a position in IBIO in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q2 2021. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

  • Rockefeller Capital Management reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 2 iBio shares in Q1 2022.
  • Rockefeller Capital Management first reported a position in iBio in Q2 2021 and held it in 3 quarters.
  • Rockefeller Capital Management's iBio position peaked at $2K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Rockefeller Capital Management's 13F filing for Q1 2022, filed 13 May 2022.